Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors

Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated do...

Descripción completa

Detalles Bibliográficos
Autores principales: Esaki, Taito, Hirai, Fumihiko, Makiyama, Akitaka, Seto, Takashi, Bando, Hideaki, Naito, Yoichi, Yoh, Kiyotaka, Ishihara, Kae, Kakizume, Tomoyuki, Natsume, Kazuto, Myers, Andrea, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447844/
https://www.ncbi.nlm.nih.gov/pubmed/30724423
http://dx.doi.org/10.1111/cas.13956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447844/
https://www.ncbi.nlm.nih.gov/pubmed/30724423
http://dx.doi.org/10.1111/cas.13956

Ejemplares similares